A Study of LAD191 in Adults With Hidradenitis Suppurativa

Inclusion Criteria: * Aged greater than or equal to (\>=) 18 to less than or equal to (\<=) 65 years. * A diagnosis of moderate-to-severe HS defined as a total of \>= 5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline/Day 1 visits, with signs and symptoms of HS for at least 6 months. * HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline/Day 1 visits. * History of inadequate response, intolerance, or contraindication to a course of a systemic antibiotics for treatment of HS at the screening visit. * Regular use of over-the-counter topical antiseptics on HS lesions and agrees to regular use, throughout the entirety of the study. * Participants who are women of child-bearing potential (WOBCP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD191 during the study. Exclusion Criteria: * HS with \>20 draining tunnels at the Screening or Baseline/Day 1 visit. * Ongoing medical conditions requiring systemic immunosuppressive/immunomodulating treatments during the study. * Known hypersensitivity to LAD191 or any of its excipients. * Known hypersensitivity to adalimumab or biosimilar or any of its excipients or meeting any warning or contraindication to adalimumab treatment as per the approved prod…